UNSPSC 51111629: Clofarabine

This classification denotes a ribonucleotide reductase inhibitor and purine antagonist with the molecular formula C10H11ClFN5O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 762RDY0Y2H, chemically known as 9h-purin-6-amine, 2-chloro-9-(2-deoxy-2-fluoro-beta-d-arabinofuranosyl)- but generally known as clofarabine, which bears US NIH Compound Identifier 119182. European Medicines Agency schedules Clofarabine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21902.

UNSPSC 51111629 Clofarabine, a Commodity code, represents pharmaceutical products that state and local health agencies procure for specialized therapeutic use. The single recent state-local opportunity under this code shows activity centered on prescription fulfillment and direct manufacturer relationships rather than traditional pharmaceutical supply acquisition. The Texas Health and Human Services Commission issued a Request for Information (RFI) in March 2026 seeking vendor capabilities for a Therapeutic Pharmacy Initiative (TPI) Direct-to-Manufacturer Prescriptions program, which aims to establish direct contracting channels between the state's pharmacy benefit program and pharmaceutical manufacturers to improve prescription fulfillment efficiency and cost management. The RFI solicits information from vendors about their experience with direct contracting for self-insured employers and health plans, their capacity to negotiate contracts using net pricing models without rebates, and their ability to implement value-based or outcomes-based agreements. This represents procurement activity by a state health agency focused on restructuring pharmaceutical supply relationships rather than simply purchasing volumes of the drug itself.

The available source shows only one recent opportunity, posted by the Texas Health and Human Services Commission in March 2026, with an April 3, 2026 response deadline. No dollar values, formal evaluation criteria, site visit requirements, or set-aside designations were identified in the RFI materials. The exploratory nature of the RFI indicates the state is conducting market research to inform future formal procurement strategy and program design before issuing subsequent RFPs with established financial and temporal parameters. Geographic activity under this code is currently limited to Texas in the available record, and broader state-local procurement activity under the clofarabine commodity code cannot be characterized from the source material provided.